Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Teresa López‐Fernández, Daniel J. Lenihan et al.|European Journal of Heart Failure|2020Cited by 767
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo G. Tocchetti, Teresa López‐Fernández, Alexander R. Lyon et al.|European Journal of Heart Failure|2024Cited by 64
The Right Heart in Patients with Cancer. A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyKalliopi Keramida, Giuseppe Rosano, Dimitrios Farmakis et al.|European Journal of Heart Failure|2024Cited by 17
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic EffectsJoerg Herrmann, Joshua D. Mitchell, Ana Barac et al.|JAMA Oncology|2025Cited by 10